Springer Healthcare, part of the Springer Nature Group, announces the opening of applications for the Prix Galien Italy 2025 for drug and research innovation.
THE EVENT
The event will be held at Palazzo Verità Poeta in Verona on October 14, 2025.
The day will feature presentations of products from pharmaceutical companies participating in the Prix Galien Italy, as well as a workshop involving key stakeholders from the pharmaceutical sector. A networking aperitif is planned for the late afternoon, followed by the evening gala dinner, during which the winners will be awarded.
APPLICATIONS
Applications for the Prix Galien Italy can be submitted by national companies (or multinational companies also based in Italy) that manufacture/distribute drugs and medical devices, as well as by researchers working in Italy.
Click on the categories of interest to download the dossier template, which must be used to submit the application.
DRUGS AWARDS
» Click here to download the general participation criteria
The following award categories are planned:
Non-biological drugs, whose active ingredients are obtained through chemical synthesis.
In accordance with the definition of ‘biological drug’ provided by AIFA, the award is reserved for drugs whose active ingredient is represented by a substance produced or extracted from a biological system. This category includes biotechnological drugs produced using recombinant DNA technologies, hormones, enzymes, blood derivatives, immunoglobulins, and monoclonal antibodies (excluding immunological drugs such as sera and vaccines, or allergens, which are specifically reserved for category no. 3).
Reserved for drugs listed in the relevant AIFA list, including medicines registered in the Community Register of Orphan Medicinal Products and medicines with marketing authorization in Italy indicated for the treatment of rare diseases or conditions listed in the Orphanet register, even if not included in the Community Register of Orphan Medicinal Products.
Important note: If only one nomination is received for this award category, the category itself will not be activated, and the nominated product will be included in one of the main reference categories (chemical synthesis or biological).
In accordance with the definition provided by the EMA, Advanced Therapy Medicinal Product (ATMP) include: (a) gene therapy medicinal products, (b) somatic cell therapy medicinal products; (d) tissue-engineered products, (e) combinations of any of the aforementioned ATMPs with a medical device (combined products). The award is exclusively reserved for products classified as ATMPs by the Committee for Advanced Therapies (CAT) of EMA, and for which EMA has already published the respective ‘Summaries of scientific recommendations on the classification of advanced therapy medicinal products.’
Important note: If only one nomination is received for this award category, the category itself will not be activated, and the nominated product will be included in one of the main reference categories (chemical synthesis or biological).
Drugs on which post-authorization studies (conducted in Italy or worldwide) have been carried out, capable of confirming or redefining their efficacy and safety in the context of normal clinical practice (real-world) or, through drug investigation, contributing to the understanding of a pathology.
Important note: Only drugs approved by the EMA or AIFA before January 1, 2017, regardless of previous nominations in Italian or foreign editions of the Prix Galien, are eligible for this award category. For this specific category, drugs that have obtained additional indications after January 1, 2017, will also be accepted and evaluated in terms of the completeness of their pharmacological profile, as evidence of the development of the same drug.
Drugs that AIFA classifies as active ingredients of chemical and biological/biotechnological nature (for example, Antibody Drug Conjugate ADC).
RESEARCH AWARD®
Pharmacological Research Award in the translational, preclinical, and clinical categories in Italy.
The three awards are given respectively to the authors of a research paper conducted in Italy in the field of translational, preclinical, or clinical pharmacology, and a research project synthesis not necessarily sequential to the work.
Three researchers (one per category) will be awarded who, at the time of the application, primarily conduct their activity in Italy, within university laboratories, public or private research centers, and pharmaceutical companies. Each winner will receive a plaque and a gross amount of 3000 Euros as a prize.
Deadline
The documentation for the Drug and Research categories must be submitted by 11:59 pm (CEST, Central European Summer Time) on June 13, 2025, via e-mail (attachments in *doc, *docx, *pdf format) to the following address: shcmilan@springer.com, with a copy to marianna.pasqua@springer.com and alessandro.gallo@springer.com.
Please specify in the subject line of the e-mail: “Application for Prix Galien Italy 2025.”
